High-Dose, Long-Term, Continuous Subcutaneous Infusion of SMS 201–995 (Sandostatin®) in Acromegaly
Acute and chronic studies have demonstrated the effectiveness of the long-acting somatostatin analogue SMS 201–995 (Sandostatin®) in the treatment of acromegaly. Daily doses of 100–300 µg Sandostatin given as multiple injections in most cases induce satisfactory suppression of GH release. No consistent shrinkage of the pituitary tumour has been demonstrated.
KeywordsToxicity Dopamine Shrinkage Statin Cose
Unable to display preview. Download preview PDF.